(NASDAQ: HBIO) Harvard Bioscience's forecast annual revenue growth rate of 8.1% is not forecast to beat the US Medical Instruments & Supplies industry's average forecast revenue growth rate of 22.46%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 1,551.19%.
Harvard Bioscience's revenue in 2026 is $87,371,000.On average, 4 Wall Street analysts forecast HBIO's revenue for 2026 to be $4,210,638,519, with the lowest HBIO revenue forecast at $3,914,451,224, and the highest HBIO revenue forecast at $4,474,906,773.
In 2027, HBIO is forecast to generate $4,387,976,426 in revenue, with the lowest revenue forecast at $4,215,898,919 and the highest revenue forecast at $4,517,257,454.